315 related articles for article (PubMed ID: 19861407)
1. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD
Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407
[TBL] [Abstract][Full Text] [Related]
2. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
3. Selective hormone-dependent repression of estrogen receptor beta by a p38-activated ErbB2/ErbB3 pathway.
St-Laurent V; Sanchez M; Charbonneau C; Tremblay A
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):23-37. PubMed ID: 15862947
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro.
Ma C; Lin H; Leonard SS; Shi X; Ye J; Luo J
Oncogene; 2003 Aug; 22(34):5281-90. PubMed ID: 12917629
[TBL] [Abstract][Full Text] [Related]
5. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Wang S; Huang X; Lee CK; Liu B
Oncogene; 2010 Jul; 29(29):4225-36. PubMed ID: 20498641
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
[TBL] [Abstract][Full Text] [Related]
7. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
8. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
Julien SG; Dubé N; Read M; Penney J; Paquet M; Han Y; Kennedy BP; Muller WJ; Tremblay ML
Nat Genet; 2007 Mar; 39(3):338-46. PubMed ID: 17259984
[TBL] [Abstract][Full Text] [Related]
9. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.
Nguyen A; Rosner A; Milovanovic T; Hope C; Planutis K; Saha B; Chaiwun B; Lin F; Imam SA; Marsh JL; Holcombe RF
Int J Oncol; 2005 Oct; 27(4):949-56. PubMed ID: 16142310
[TBL] [Abstract][Full Text] [Related]
10. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
Alimandi M; Romano A; Curia MC; Muraro R; Fedi P; Aaronson SA; Di Fiore PP; Kraus MH
Oncogene; 1995 May; 10(9):1813-21. PubMed ID: 7538656
[TBL] [Abstract][Full Text] [Related]
11. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
Huang X; Gao L; Wang S; Lee CK; Ordentlich P; Liu B
Cancer Res; 2009 Nov; 69(21):8403-11. PubMed ID: 19826038
[TBL] [Abstract][Full Text] [Related]
12. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function.
Ishizawar RC; Miyake T; Parsons SJ
Oncogene; 2007 May; 26(24):3503-10. PubMed ID: 17173075
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
14. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
[TBL] [Abstract][Full Text] [Related]
15. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
Ursini-Siegel J; Rajput AB; Lu H; Sanguin-Gendreau V; Zuo D; Papavasiliou V; Lavoie C; Turpin J; Cianflone K; Huntsman DG; Muller WJ
Mol Cell Biol; 2007 Sep; 27(18):6361-71. PubMed ID: 17636013
[TBL] [Abstract][Full Text] [Related]
16. ErbB kinases and NDF signaling in human prostate cancer cells.
Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
[TBL] [Abstract][Full Text] [Related]
17. ErbB3-dependent motility and intravasation in breast cancer metastasis.
Xue C; Liang F; Mahmood R; Vuolo M; Wyckoff J; Qian H; Tsai KL; Kim M; Locker J; Zhang ZY; Segall JE
Cancer Res; 2006 Feb; 66(3):1418-26. PubMed ID: 16452197
[TBL] [Abstract][Full Text] [Related]
18. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
19. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
Efferson CL; Winkelmann CT; Ware C; Sullivan T; Giampaoli S; Tammam J; Patel S; Mesiti G; Reilly JF; Gibson RE; Buser C; Yeatman T; Coppola D; Winter C; Clark EA; Draetta GF; Strack PR; Majumder PK
Cancer Res; 2010 Mar; 70(6):2476-84. PubMed ID: 20197467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
